0620/24SCR019-18/R10
Media Highlights
From the 2024 ASCO® Annual Meeting
3
Media Outlet Article / Coverage
eCancer Adagrasib Improves on Docetaxel in Previously Treated NSCLC
Robert Jotte, MD, PhD
SCRI at Rocky Mountain Cancer Centers
Media Outlet Article / Coverage
OncoZine ASCO 2024: Encouraging Dose Escalation Data from Ongoing
Phase 1 KisMET-01 Study of MYTX-011
Melissa Johnson, MD
SCRI
Media Outlet Article / Coverage
VJ Oncology 'ASCO 2024 | Updated Survival Results of DESTINY-Breast03:
T-DXd vs T-DM1 in HER2+ Metastatic Breast Cancer
VJ Oncology 'ASCO 2024 | The ABCs of ADCs: What Does The Future Hold?
VJ Oncology 'ASCO 2024 | H3B-6545 in Women with Locally Advanced/
Metastatic ER+, HER2 Negative Breast Cancer
VJ Oncology 'ASCO 2024 | Promising Targets in ADCs for Breast Cancer
VuMedi ASCO® 2024 Insights: "H3B-6545 in Women With ER+/HER2-
mBC"
VuMedi ASCO® 2024 Insights: "The ABCs of ADCs - What Does the
Future Hold?"
VuMed ASCO® 2024 Insights: "Updated Survival Data in DESTINY-
Breast03 Trial - T-DXd vs. T-DM1 in Patients With HER2+ mBC"
Erika Hamilton, MD
SCRI
